Copyright Reports & Markets. All rights reserved.

China Pulmonary Drugs Market Report 2018

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Definition and Specification
    • 1.2 Report Overview
      • 1.2.1 Manufacturers Overview
      • 1.2.2 Regions Overview
      • 1.2.3 Type Overview
      • 1.2.4 Application Overview
    • 1.3 Industrial Chain
      • 1.3.1 Pulmonary Drugs Overall Industrial Chain
      • 1.3.2 Upstream
      • 1.3.3 Downstream
    • 1.4 Industry Situation
      • 1.4.1 Industrial Policy
      • 1.4.2 Product Preference
      • 1.4.3 Economic/Political Environment
    • 1.5 SWOT Analysis

    2 Market Analysis by Types

    • 2.1 Overall Market Performance(Volume)
      • 2.1.1 Inhaled Corticosteroids (ICS) Market Performance (Volume)
      • 2.1.2 Long-Acting Beta2-Agonists (LABA) Market Performance (Volume)
      • 2.1.3 Antihistamine Market Performance (Volume)
      • 2.1.4 Vasodilators Market Performance (Volume)
      • 2.1.5 Short-Acting Beta2-Agonists (SABA) Market Performance (Volume)
    • 2.2 Overall Market Performance(Value)
      • 2.1.1 Inhaled Corticosteroids (ICS) Market Performance (Value)
      • 2.1.2 Long-Acting Beta2-Agonists (LABA) Market Performance (Value)
      • 2.1.3 Antihistamine Market Performance (Value)
      • 2.1.4 Vasodilators Market Performance (Value)
      • 2.1.5 Short-Acting Beta2-Agonists (SABA) Market Performance (Value)

    3 Product Application Market

    • 3.1 Overall Market Performance (Volume)
      • 3.1.1 Asthma & COPD Market Performance (Volume)
      • 3.1.2 Allergic Rhinitis Market Performance (Volume)
      • 3.1.3 Pulmonary Arterial Hypertension Market Performance (Volume)
      • 3.1.4 Cystic Fibrosis Market Performance (Volume)

    4 Manufacturers Profiles/Analysis

    • 4.1 AstraZeneca plc
      • 4.1.1 AstraZeneca plc Profiles
      • 4.1.2 AstraZeneca plc Product Information
      • 4.1.3 AstraZeneca plc Pulmonary Drugs Business Performance
      • 4.1.4 AstraZeneca plc Pulmonary Drugs Business Development and Market Status
    • 4.2 Bayer AG?
      • 4.2.1 Bayer AG? Profiles
      • 4.2.2 Bayer AG? Product Information
      • 4.2.3 Bayer AG? Pulmonary Drugs Business Performance
      • 4.2.4 Bayer AG? Pulmonary Drugs Business Development and Market Status
    • 4.3 Teva Pharmaceutical Industries Ltd.?
      • 4.3.1 Teva Pharmaceutical Industries Ltd.? Profiles
      • 4.3.2 Teva Pharmaceutical Industries Ltd.? Product Information
      • 4.3.3 Teva Pharmaceutical Industries Ltd.? Pulmonary Drugs Business Performance
      • 4.3.4 Teva Pharmaceutical Industries Ltd.? Pulmonary Drugs Business Development and Market Status
    • 4.4 Actelion Pharmaceuticals, Inc.
      • 4.4.1 Actelion Pharmaceuticals, Inc. Profiles
      • 4.4.2 Actelion Pharmaceuticals, Inc. Product Information
      • 4.4.3 Actelion Pharmaceuticals, Inc. Pulmonary Drugs Business Performance
      • 4.4.4 Actelion Pharmaceuticals, Inc. Pulmonary Drugs Business Development and Market Status
    • 4.5 Boehringer Ingelheim GmbH
      • 4.5.1 Boehringer Ingelheim GmbH Profiles
      • 4.5.2 Boehringer Ingelheim GmbH Product Information
      • 4.5.3 Boehringer Ingelheim GmbH Pulmonary Drugs Business Performance
      • 4.5.4 Boehringer Ingelheim GmbH Pulmonary Drugs Business Development and Market Status
    • 4.6 F. Hoffmann-La Roche Ltd.
      • 4.6.1 F. Hoffmann-La Roche Ltd. Profiles
      • 4.6.2 F. Hoffmann-La Roche Ltd. Product Information
      • 4.6.3 F. Hoffmann-La Roche Ltd. Pulmonary Drugs Business Performance
      • 4.6.4 F. Hoffmann-La Roche Ltd. Pulmonary Drugs Business Development and Market Status
    • 4.7 Merck & Co., Inc.
      • 4.7.1 Merck & Co., Inc. Profiles
      • 4.7.2 Merck & Co., Inc. Product Information
      • 4.7.3 Merck & Co., Inc. Pulmonary Drugs Business Performance
      • 4.7.4 Merck & Co., Inc. Pulmonary Drugs Business Development and Market Status
    • 4.8 Novartis AG
      • 4.8.1 Novartis AG Profiles
      • 4.8.2 Novartis AG Product Information
      • 4.8.3 Novartis AG Pulmonary Drugs Business Performance
      • 4.8.4 Novartis AG Pulmonary Drugs Business Development and Market Status
    • 4.9 GlaxoSmithKline plc
      • 4.9.1 GlaxoSmithKline plc Profiles
      • 4.9.2 GlaxoSmithKline plc Product Information
      • 4.9.3 GlaxoSmithKline plc Pulmonary Drugs Business Performance
      • 4.9.4 GlaxoSmithKline plc Pulmonary Drugs Business Development and Market Status
    • 4.10 Sunovion Pharmaceuticals, Inc.?
      • 4.10.1 Sunovion Pharmaceuticals, Inc.? Profiles
      • 4.10.2 Sunovion Pharmaceuticals, Inc.? Product Information
      • 4.10.3 Sunovion Pharmaceuticals, Inc.? Pulmonary Drugs Business Performance
      • 4.10.4 Sunovion Pharmaceuticals, Inc.? Pulmonary Drugs Business Development and Market Status

    5 Market Performance for Manufacturers

    • 5.1 China Pulmonary Drugs Sales (K Units) and Market Share by Manufacturers 2013-2018
    • 5.2 China Pulmonary Drugs Revenue (M USD) and Market Share by Manufacturers 2013-2018
    • 5.3 China Pulmonary Drugs Price (USD/Unit) of Manufacturers 2013-2018
    • 5.4 China Pulmonary Drugs Gross Margin of Manufacturers 2013-2018
    • 5.5 Market Concentration

    6 Regions Market Performance for Manufacturers

    • 6.1 South China Market Performance for Manufacturers
      • 6.1.1 South China Pulmonary Drugs Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.1.2 South China Pulmonary Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.1.3 South China Pulmonary Drugs Price (USD/Unit) of Manufacturers 2013-2018
      • 6.1.4 South China Pulmonary Drugs Gross Margin of Manufacturers 2013-2018
      • 6.1.5 Market Concentration
    • 6.2 East China Market Performance for Manufacturers
      • 6.2.1 East China Pulmonary Drugs Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.2.2 East China Pulmonary Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.2.3 East China Pulmonary Drugs Price (USD/Unit) of Manufacturers 2013-2018
      • 6.2.4 East China Pulmonary Drugs Gross Margin of Manufacturers 2013-2018
      • 6.2.5 Market Concentration
    • 6.3 Southwest China Market Performance for Manufacturers
      • 6.3.1 Southwest China Pulmonary Drugs Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.3.2 Southwest China Pulmonary Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.3.3 Southwest China Pulmonary Drugs Price (USD/Unit) of Manufacturers 2013-2018
      • 6.3.4 Southwest China Pulmonary Drugs Gross Margin of Manufacturers 2013-2018
      • 6.3.5 Market Concentration
    • 6.4 Northeast China Market Performance for Manufacturers
      • 6.4.1 Northeast China Pulmonary Drugs Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.4.2 Northeast China Pulmonary Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.4.3 Northeast China Pulmonary Drugs Price (USD/Unit) of Manufacturers 2013-2018
      • 6.4.4 Northeast China Pulmonary Drugs Gross Margin of Manufacturers 2013-2018
      • 6.4.5 Market Concentration
    • 6.5 North China Market Performance for Manufacturers
      • 6.5.1 North China Pulmonary Drugs Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.5.2 North China Pulmonary Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.5.3 North China Pulmonary Drugs Price (USD/Unit) of Manufacturers 2013-2018
      • 6.5.4 North China Pulmonary Drugs Gross Margin of Manufacturers 2013-2018
      • 6.5.5 Market Concentration
    • 6.6 Central China Market Performance for Manufacturers
      • 6.6.1 Central China Pulmonary Drugs Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.6.2 Central China Pulmonary Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.6.3 Central China Pulmonary Drugs Price (USD/Unit) of Manufacturers 2013-2018
      • 6.6.4 Central China Pulmonary Drugs Gross Margin of Manufacturers 2013-2018
      • 6.6.5 Market Concentration
    • 6.7 Northwest China Market Performance for Manufacturers
      • 6.7.1 Northwest China Pulmonary Drugs Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.7.2 Northwest China Pulmonary Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.7.3 Northwest China Pulmonary Drugs Price (USD/Unit) of Manufacturers 2013-2018
      • 6.7.4 Northwest China Pulmonary Drugs Gross Margin of Manufacturers 2013-2018
      • 6.7.5 Market Concentration

    7 China Pulmonary Drugs Market Performance (Sales Point)

    • 7.1 China Pulmonary Drugs Sales (K Units) and Market Share by Regions 2013-2018
    • 7.2 China Pulmonary Drugs Revenue (M USD) and Market Share by Regions 2013-2018
    • 7.3 China Pulmonary Drugs Price (USD/Unit) by Regions 2013-2018
    • 7.4 China Pulmonary Drugs Gross Margin by Regions 2013-2018

    8 Development Trend for Regions (Sales Point)

    • 8.1 China Pulmonary Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.2 South China Pulmonary Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.3 East China Pulmonary Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.4 Southwest China Pulmonary Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.5 Northeast China Pulmonary Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.6 North China Pulmonary Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.7 Central China Pulmonary Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.8 Northwest China Pulmonary Drugs Sales and Growth, Sales Value and Growth Rate2013-2018

    9 Upstream Source, Technology and Cost

    • 9.1 Upstream Source
    • 9.2 Technology
    • 9.3 Cost

    10 Channel Analysis

    • 10.1 Market Channel
    • 10.2 Distributors

    11 Consumer Analysis

    • 11.1 Asthma & COPD Industry
    • 11.2 Allergic Rhinitis Industry
    • 11.3 Pulmonary Arterial Hypertension Industry

    12 Market Forecast 2019-2024

    • 12.1 Sales (K Units), Revenue (M USD), Market Share and Growth Rate 2019-2024
      • 12.1.1 China Pulmonary Drugs Sales (K Units), Revenue (M USD) and Market Share by Regions 2019-2024
      • 12.1.2 China Pulmonary Drugs Sales (K Units) and Growth Rate 2019-2024
      • 12.1.3 South China Pulmonary Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.4 East China Pulmonary Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.5 Southwest China Pulmonary Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.6 Northeast China Pulmonary Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.7 North China Pulmonary Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.8 Central China Pulmonary Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.9 Northwest China Pulmonary Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
    • 12.3 Sales (K Units), Revenue (M USD) by Types 2019-2024
      • 12.3.1 Overall Market Performance
      • 12.3.2 Inhaled Corticosteroids (ICS) Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.3.3 Long-Acting Beta2-Agonists (LABA) Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.3.4 Antihistamine Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.3.5 Vasodilators Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
    • 12.4 Sales by Application 2019-2024
      • 12.4.1 Overall Market Performance
      • 12.4.2 Asthma & COPD Sales and and Growth Rate 2019-2024
      • 12.4.3 Allergic Rhinitis Sales and and Growth Rate 2019-2024
      • 12.4.4 Pulmonary Arterial Hypertension Sales and and Growth Rate 2019-2024
      • 12.4.5 Cystic Fibrosis Sales and and Growth Rate 2019-2024
    • 12.5 Price (USD/Unit) and Gross Profit
      • 12.5.1 China Pulmonary Drugs Price (USD/Unit) Trend 2019-2024
      • 12.5.2 China Pulmonary Drugs Gross Profit Trend 2019-2024

    13 Conclusion

    Geographically, this report split China into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Pulmonary Drugs for these regions, from 2012 to 2023 (forecast), including
    South China
    East China
    Southwest China
    Northeast China
    North China
    Central China
    Northwest China

    China Pulmonary Drugs market competition by top manufacturers/players, with Pulmonary Drugs sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    AstraZeneca plc
    Bayer AG?
    Teva Pharmaceutical Industries Ltd.?
    Actelion Pharmaceuticals, Inc.
    Boehringer Ingelheim GmbH
    F. Hoffmann-La Roche Ltd.
    Merck & Co., Inc.
    Novartis AG
    GlaxoSmithKline plc
    Sunovion Pharmaceuticals, Inc.?

    On the basis of product, this report displays the sales volume (K Units), revenue (Million USD), product price (USD/Unit), market share and growth rate of each type, primarily split into
    Inhaled Corticosteroids (ICS)
    Long-Acting Beta2-Agonists (LABA)
    Antihistamine
    Vasodilators
    Short-Acting Beta2-Agonists (SABA)
    Anticholinergics
    ? ? Combination Drugs
    ? ? MAbs
    ? ? Enzymes
    ? ? Antibiotics & Antileukotrienes

    On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K Units), market share and growth rate of Pulmonary Drugs for each application, including
    Asthma & COPD
    Allergic Rhinitis
    Pulmonary Arterial Hypertension
    Cystic Fibrosis

    If you have any special requirements, please let us know and we will offer you the report as you want.

    Buy now